– CANADA, Quebec City – Devonian Health Group Inc. (TSX: GSD), a clinical-stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced the appointment of Martin Moreau to its board of directors as VP Finance, effective September 27, 2021.
“Martin is a renowned leader in the field of entrepreneurship, business management and finance, making him an ideal fit for Devonian’s executive team. This is an exciting time for Devonian on the heels of our recent phase 2 clinical trial results in Atopic Dermatitis. We are thrilled to welcome Martin and are confident that his track record in capital management and financing will be invaluable as we pursue partnership opportunities and advance multiple assets through the clinic and ultimately to the market.” said Dr. André Boulet, CEO and Chairman.
About Martin Moreau
Mr. Moreau started his career with CDP Capital Technologies, a venture capital firm, where he acted as Investment Analyst in the industrial and biotechnology sectors. From 2003 to 2010, he is appointed Director of Finance at Safe Life Corporation, an antimicrobial technology, and infection prevention company. He is part of the team who has raised more than $80 million in new fundings, in addition to proceeding to the financial analyses of several projects, like the opening of a production facility in Asia. He subsequently co-founded three seniors’ residences, these housing projects totaling more than $150 million. He also acquired Marchand Entrepreneur Électricien Ltée in 2012, and successfully developed the company to the point of making it a recognized industry leader, using seven acquisitions and mergers with its competitors. In 2021, he acquired Fixations Shur-Fast Inc., a leading North American manufacturer of precision nails and staples, in business for over 50 years.
Martin Moreau commented: “I am glad to join Devonian Health Group inc. Recent clinical results support our ambition to make it a major player in the field of inflammatory diseases and it is an honor for me to participate in the development of the company.”
About Devonian
Devonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian’s flagship product, Thykamine, the first pharmaceutical product issued from Devonian’s SUPREX platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and a large phase 2 clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis. The product is now ready to move into phase 3 clinical development.
Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the-art extraction facility with full traceability ‘from the seed to the pill’. Acquired in 2018, Altius Healthcare Inc., its commercialization subsidiary, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSXV Exchange (TSX: GSD).
For more information: http://groupedevonian.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
